Walleye Trading
ADVM

Walleye Trading’s Adverum Biotechnologies ADVM Stock Holding History

Walleye Trading’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-130
Closed -$13K – 4540
2020
Q3 		$13K Buy
+130
New +$19.5K ﹤0.01% 3878
2020
Q2 		– Sell
-120
Closed -$12K – 4194
2020
Q1 		$12K Buy
+120
New +$14K ﹤0.01% 3692

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Trading's ADVM Position: Q3 2021 in Review

Walleye Trading sold out of Adverum Biotechnologies (ADVM) in Q3 2021, closing a stake of 5,471 shares — an estimated $191K sold.

Walleye Trading first reported a position in ADVM in Q1 2016 and held it in 4 quarters. The position peaked at $248K in Q3 2020. 110 funds tracked by Wall St. Rank hold ADVM as of Q3 2021.

  • Walleye Trading reported no remaining Adverum Biotechnologies position as of Q3 2021 after selling out during the quarter.
  • Walleye Trading sold 5,471 Adverum Biotechnologies shares in Q3 2021, an estimated $191K.
  • Walleye Trading first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 4 quarters.
  • Walleye Trading's Adverum Biotechnologies position peaked at $248K in Q3 2020.
  • 110 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.